precision oncology
It also announced its collaboration with an unnamed liquid biopsy company.
The lab will be providing drug testing platform services to oncologists and pharmaceutical firms.
The roughly three-year-old company says it now has a post-money valuation over $1 billion.
A interview with Prof Yasushi Goto, Department of Thoracic Oncology, National Cancer Center Hospital, Japan.
The companies' partnership is yet another example of real-world data analysis coming to clinical trials.
Although still far from being tested in humans, the technology could serve as a replacement to blood draws.
Launched in 2010 with a $25 million Series A financing led by Third Rock Ventures, Foundation Medicine released its first commercial assay called FoundationOne in 2012.
Roche announced last week the launch of FoundationOne CDx, Foundation Medicine’s comprehensive companion diagnostic test for personalised cancer care in Singapore.
The Department of Veterans Affairs and IBM Watson Health have announced a one-year extension to an ongoing public-private partnership applying the AI company’s technology to genomic data for cancer therapy.